SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension

NCT ID: NCT01418261

Last Updated: 2017-04-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

535 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2017-02-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uncontrolled Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Renal Denervation

Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications

Group Type EXPERIMENTAL

Renal denervation (Symplicity Catheter System)

Intervention Type DEVICE

Renal angiogram

Intervention Type DIAGNOSTIC_TEST

Control group

Subjects go through renal angiogram and Subjects maintained baseline anti-hypertensive medications

Group Type SHAM_COMPARATOR

Renal angiogram

Intervention Type DIAGNOSTIC_TEST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renal denervation (Symplicity Catheter System)

Intervention Type DEVICE

Renal angiogram

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individual is ≥ 18 and ≤ 80 years old at time of randomization.
* Individual is receiving a stable medication regimen including full tolerated doses of 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic (with no changes for a minimum of 2 weeks prior to screening) that is expected to be maintained without changes for at least 6 months.
* Individual has an office systolic blood pressure (SBP) of ≥ 160 mmHg based on an average of 3 blood pressure readings measured at both an initial screening visit and a confirmatory screening visit

Exclusion Criteria

* Individual has an estimated glomerular filtration rate (eGFR) of \< 45 mL/min/1.73 m2
* Individual has an Ambulatory Blood Pressure Monitoring (ABPM) 24 hour average SBP \< 135 mmHg
* Individual has type 1 diabetes mellitus
* Individual requires chronic oxygen support or mechanical ventilation (e.g., tracheostomy, CPAP, BiPAP) other than nocturnal respiratory support for sleep apnea.
* Individual has primary pulmonary hypertension.
* Individual is pregnant, nursing or planning to be pregnant.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Vascular

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

George Bakris, MD

Role: PRINCIPAL_INVESTIGATOR

Professor of Medicine, Hypertension Center Director University of Chicago Medical Center

Deepak L Bhatt, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

VA Boston Healthcare System Department of Cardiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiology, PC

Birmingham, Alabama, United States

Site Status

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Scripps Clinic/Scripps Green Hospital

La Jolla, California, United States

Site Status

Kaiser Permanente - Los Angeles Medical Center

Los Angeles, California, United States

Site Status

Cedars Sinai Medical Center

Los Angeles, California, United States

Site Status

St. Joseph Hospital

Orange, California, United States

Site Status

San Diego Cardiac Center

San Diego, California, United States

Site Status

Stanford University

Stanford, California, United States

Site Status

University of Colorado Hospital

Aurora, Colorado, United States

Site Status

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Howard University Hospital

Washington D.C., District of Columbia, United States

Site Status

Shands / University of Florida

Gainesville, Florida, United States

Site Status

Mayo Clinic

Jacksonville, Florida, United States

Site Status

University Of Miami

Miami, Florida, United States

Site Status

Baptist Cardiac &Vascular Institute, Baptist Health Systems

Miami, Florida, United States

Site Status

Tampa General Hospital

Tampa, Florida, United States

Site Status

Emory University Hospital Midtown

Atlanta, Georgia, United States

Site Status

Piedmont Heart Institute

Atlanta, Georgia, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Midwest Heart Foundation

Oakbrook Terrace, Illinois, United States

Site Status

Prairie Heart Institute

Springfield, Illinois, United States

Site Status

Iowa Heart Center Research

Des Moines, Iowa, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

Ochsner Medical Center

New Orleans, Louisiana, United States

Site Status

University of Maryland, Baltimore

Baltimore, Maryland, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

VA Boston Healthcare System

Boston, Massachusetts, United States

Site Status

Lahey Clinic

Burlington, Massachusetts, United States

Site Status

UMass Memorial Medical Center

Worcester, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Harper University Hospital - Detroit Medical Center

Detroit, Michigan, United States

Site Status

St Joseph Mercy Oakland Hospital

Pontiac, Michigan, United States

Site Status

Providence Hospital

Southfield, Michigan, United States

Site Status

Michigan Heart, St. Joseph Mercy Health System

Ypsilanti, Michigan, United States

Site Status

Abbott Northwestern/Minneapolis Heart Institute Foundation

Minneapolis, Minnesota, United States

Site Status

Saint Mary's Mayo Clinic

Rochester, Minnesota, United States

Site Status

Hattiesburg Clinic, P.A

Hattiesburg, Mississippi, United States

Site Status

Saint Luke's Hospital of Kansas City/Mid America Heart Institute

Kansas City, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Deborah Heart & Lung Center

Browns Mills, New Jersey, United States

Site Status

Morristown Medical Center

Morristown, New Jersey, United States

Site Status

Jersey Shore University Medical Center

Neptune City, New Jersey, United States

Site Status

SUNY Downstate Medical Center

Brooklyn, New York, United States

Site Status

New York University Medical Center

New York, New York, United States

Site Status

Weill Cornell Medical College

New York, New York, United States

Site Status

Mount Sinai Medical Center-Manhattan

New York, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

St. Francis Hospital

Roslyn, New York, United States

Site Status

Stony Brook University Hospital and Medical Center

Stony Brook, New York, United States

Site Status

University of North Carolina Heart and Vascular

Chapel Hill, North Carolina, United States

Site Status

Carolinas Healthcare (SHVI)-Clinical Research

Charlotte, North Carolina, United States

Site Status

Duke University Health System

Durham, North Carolina, United States

Site Status

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

Site Status

The Lindner Center for Research & Education at The Christ Hospital

Cincinnati, Ohio, United States

Site Status

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Site Status

The MetroHealth System

Cleveland, Ohio, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

The Ohio State University

Columbus, Ohio, United States

Site Status

OhioHealth Research Institute

Columbus, Ohio, United States

Site Status

Geisinger Medical Center

Danville, Pennsylvania, United States

Site Status

Lancaster General Hospital

Lancaster, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospitals, Inc

Philadelphia, Pennsylvania, United States

Site Status

University of Pennsylvania Health System

Philadelphia, Pennsylvania, United States

Site Status

UPMC

Pittsburgh, Pennsylvania, United States

Site Status

Lankenau Medical Center

Wynnewood, Pennsylvania, United States

Site Status

Vascular Disease Research Center at Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Stern Cardiovascular Foundation, Inc.

Memphis, Tennessee, United States

Site Status

Vanderbilt Medical Center

Nashville, Tennessee, United States

Site Status

Austin Heart PLLC / Heart Hospital of Austin

Austin, Texas, United States

Site Status

VA North Texas Health Care System

Dallas, Texas, United States

Site Status

Soltero Cardiovascular Research Center - Baylor Jack and Jane Hamilton Heart & Vascular Hospital

Dallas, Texas, United States

Site Status

The Methodist Hospital

Houston, Texas, United States

Site Status

The Heart Hospital Baylor Plano

Plano, Texas, United States

Site Status

Fletcher Allen Health Care

Burlington, Vermont, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status

Aurora St. Luke's Medical Center

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL; SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 Oct 22;400(10361):1405-1416. doi: 10.1016/S0140-6736(22)01787-1. Epub 2022 Sep 18.

Reference Type DERIVED
PMID: 36130612 (View on PubMed)

Mahfoud F, Bakris G, Bhatt DL, Esler M, Ewen S, Fahy M, Kandzari D, Kario K, Mancia G, Weber M, Bohm M. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017 Jan 7;38(2):93-100. doi: 10.1093/eurheartj/ehw325.

Reference Type DERIVED
PMID: 28158510 (View on PubMed)

Pocock SJ, Bakris G, Bhatt DL, Brar S, Fahy M, Gersh BJ. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. J Am Coll Cardiol. 2016 Nov 1;68(18):2016-2025. doi: 10.1016/j.jacc.2016.07.775.

Reference Type DERIVED
PMID: 27788856 (View on PubMed)

Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec;66(6):1130-7. doi: 10.1161/HYPERTENSIONAHA.115.06260. Epub 2015 Oct 5.

Reference Type DERIVED
PMID: 26558819 (View on PubMed)

Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 7;65(13):1314-1321. doi: 10.1016/j.jacc.2015.01.037.

Reference Type DERIVED
PMID: 25835443 (View on PubMed)

Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21;36(4):219-27. doi: 10.1093/eurheartj/ehu441. Epub 2014 Nov 16.

Reference Type DERIVED
PMID: 25400162 (View on PubMed)

Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014 Sep 16;64(11):1071-8. doi: 10.1016/j.jacc.2014.05.012. Epub 2014 May 20.

Reference Type DERIVED
PMID: 24858423 (View on PubMed)

Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10;370(15):1393-401. doi: 10.1056/NEJMoa1402670. Epub 2014 Mar 29.

Reference Type DERIVED
PMID: 24678939 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IP125

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sympathetic Mapping/ Ablation of Renal Nerves Trial
NCT02761811 ACTIVE_NOT_RECRUITING NA
Symplicity China Study
NCT07081243 RECRUITING
Renal Denervation in Hypertension
NCT01570777 COMPLETED PHASE4
SMART Study in Real World
NCT06780696 NOT_YET_RECRUITING